neuroinflammatory

Neuroinflammatory-IN-2 (compound 7i) is a potent anti-neuroinflammatory agent, capable of acting on MAO-B (IC50: 10.30 μM). Neuroinflammatory-IN-2 inhibits 96.33% of Aβ1-42 aggregation at 25 μM. Neuroinflammatory-IN-2 exhibits neuroprotective activity in H2O2-induced PC-12 cell injury. Neuroinflammatory-IN-2 can be used to study Alzheimer's disease.

Neuroinflammatory-IN-3 is a tubulin inhibitor that serves as both an anti-neuroinflammatory agent and a potent antitumor agent by inhibiting tubulin polymerization.

Neuroinflammatory-IN-1 (Compound 5) is an anti-neuroinflammatory agent that inhibits nitric oxide (NO) production with an IC50 of 65.4 μM [1].

MW01-2-151SRM is a novel small molecule inhibitor of microglia activation that crosses the blood-brain barrier, has anti-neuroinflammatory effects, attenuates the up-regulation of glial cytokines in models of neuroinflammation, and can be used in studies of traumatic brain injury, Alzheimer's disease, and alginate toxicity.

Polygalasaponin F has anti-neuroinflammatory activity, can inhibit the release of inflammatory cytokines TNF-α and NO induced by lipopolysaccharides (LPS) and reduce the expression of inducible nitric oxide synthases. Polygalasaponin F can significantly i

1. Schisandrol B (Besigomsin) may exert neuroprotective effects by attenuating the microglia-mediated neuroinflammatory response via inhibiting the TLR4-mediated NF-κB and MAPKs signaling pathways. 2. Schisandrol B has anti-inflammatory property, potentially result from the inhibition of COX-2, iNOS, IL-6, TNF-α and NO through the down-regulation of RIP2 and NF-κB activation. 3. Schisandrol B induces marked protective effects against hepatic and renal injury induced by CCl(4) exposure through differential regulation of the MAPK signal transduction pathway. 4. Schisandrol B significantly inhibits cell proliferation in a dose-dependent manner, due to cell cycle arrest in the G1 phase with the downregulation of cyclin D1 expression and Retinoblastoma (RB) phosphorylation.

TQS (4-Naphthalen-1-yl-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide) is a positive allosteric modulator of α7 nACh receptors.

Aurantiamide has anti-cancer, anti-inflammatory and antinociceptive activities, it may suppress the growth of malignant gliomas by blocking autophagic flux.Aurantiamide has an anti-neuroinflammatory effect on LPS stimulation through its inhibition of the

γ-Fibrinogen377-395 TFA is an inhibitory peptide derived from fibrinogen, which also functions as a fibrinogen epitope. It effectively blocks microglial activation and impedes fibrin-Mac-1 interactions in vitro. Additionally, it exhibits in vivo efficacy by suppressing experimental autoimmune encephalomyelitis (EAE) in mice. This compound has applications in researching multiple sclerosis (MS) and other neuroinflammatory diseases linked to blood-brain barrier disruption and microglial activation [1].

ARN-6039, an orally available inverse agonist of RORγ, targets Autoimmune Neuroinflammatory Demyelinating Disease. Its efficacy was demonstrated in a RORγ-activated IL-17A Prom LUCPorter assay in HEK 293 cells (360 nM) and in IL-17 release from CD4+T cell assays (220 nM).

PKM2-IN-3 is a potent PKM2 kinase inhibitor, displaying an IC 50 value of 4.1 μM. The compound effectively suppresses PKM2-mediated glycolysis and NLRP3 activation, thereby exerting an anti-neuroinflammatory effect.

Artemisinin B is a drug which may improve spatial memory in dementia patients and alter the levels of inflammatory cytokines in the hippocampus and the cortex. Artemisinin B may inhibit neuroinflammation and exert neuroprotective effects on cognitive functions by modulating the TLR4-MyD88-NF-κB signaling pathway. Artemisinin B has shown potential in the treatment of neuroinflammatory diseases.

RV01 is a novel quinoline-substituted analogue of resveratrol that inhibits DNA damage, reduces ethanol-induced acetaldehyde dehydrogenase (ALDH2) mRNA expression, and has hydroxyl radical scavenging activity. rV01 reduces iNOS expression and has anti-neuroinflammatory effects. rV01 reduces tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) mRNA levels and secretion. RV01 reduced tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) mRNA levels and secretion, inhibited lps-induced ROS production and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation, decreased toll-like receptor 4 (TLR4) protein expression, and inhibited lps-induced activation of mitogen-activated protein kinase (MAPK) and nuclear transcription factor-кB (NF-кB) signaling pathways.

LZWL02003, an anti-neuroinflammatory agent, demonstrates a protective effect on MPP+-induced neuronal damage and reduces ROS expression. Additionally, it enhances cognition, memory, learning, and athleticism in Rotenone-induced Parkinson's disease (PD) rat models, suggesting its potential for neurodegenerative disease research [1].

MAPK-IN-1 (Compound 2) is an inhibitor of the MAPK signaling pathway with anti-neuroinflammatory and neuroprotective activities, suitable for Alzheimer's disease research. It inhibits AChE with an IC50 of 23.84 μM [1].

SRI-42127 is a novel small molecule inhibitor of the RNA regulatory factor HuR, which inhibits tumor growth, attenuates glial activation in a lipopolysaccharide-induced neuroinflammation model, and reduces neuropathic pain after nerve injury by inhibiting the neuroinflammatory response.

SB26019 is a potent anti-neuroinflammatory compound that modulates the activation of NF-κB by promoting the formation of monomeric α-tubulin, thereby hindering the translocation of p65 and regulating neuroinflammatory processes [1].

Monoamine Oxidase B inhibitor 2 is a potent, reversible, orally active, and selective inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 1.33 nM, capable of crossing the blood-brain barrier (BBB). It exhibits antioxidant and anti-neuroinflammatory activities and is useful in the study of Parkinson’s disease [1].

Neoechinulin A has anti-inflammatory effect against LPS-stimulated RAW264.7 macrophages through inhibition of the NF-κB and p38 MAPK pathways, it may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regu

1. Kamebakaurin (Kamebakaurine) has the ability to protect the liver from APAP-induced hepatotoxicity, presumably by both inhibiting the inflammatory response and oxidative stress. 2. Kamebakaurin inhibits the expression of hypoxia-inducible factor-1α and its target genes to confer antitumor activity. 3. Kamebakaurin has anti-cancer and anti-inflammatory activities through direct inhibition of DNA-binding activity of nuclear factor-kappa B (NF-κB) p50.4. Kamebakaurin has anti-neuroinflammatory activity via inhibition of c-Jun NH -terminal kinase and p38 mitogen-activated protein kinase pathway in activated microglial cells.

1. beta-Asarone (Cis-Isoelemicin) may be a potential preventive drug for Alzheimer's disease. 2. Beta-Asarone prevents autophagy and synaptic loss by reducing ROCK expression in SAMP8 mice. 3. The co-administration of beta-Asarone(Cis-Isoasarone) and l-dopa may contribute to the treatment of 6-OHDA-induced damage in rats by inhibiting autophagy activity. 4. Beta-Asarone exhibits anti-inflammatory effects by suppressing the production of pro-inflammatory mediators through NF-κB signaling and the JNK pathways in activated microglial cells and might be developed as a promising candidate to treat various neuroinflammatory diseases.

Protosappanin A (PTA) has anti-oxidative nitrative activities on brain immune and neuroinflammation through regulation of CD14 TLR4-dependent IKK IκB NF-κB inflammation signal pathway; it exerts anti-neuroinflammatory effect by inhibiting JAK2-STAT3 pathway in lipopolysaccharide-induced BV2 microglia. Protosappanin A induces immunosuppression of rats heart transplantation targeting T cells in grafts via NF-kappaB pathway. Protosappanin A and protosappanin B have antimicrobial activity, they show both alone activities and resistance reversal effects of amikacin and gentamicin against MRSA. Protosappanin A shows strong effect against HIV-1 IN with an IC50 value of 12.6 uM.

Herpotrichone B exhibits significant anti-neuroinflammatory activity by inhibiting lipopolysaccharide (LPS)-induced inflammation in BV-2 microglial cells, demonstrating a half maximal inhibitory concentration (IC50) of 0.11 μM.

CIAC001, a pyruvate kinase PKM2 inhibitor, exhibits anti-neuroinflammatory properties. It effectively suppresses LPS-induced production of proinflammatory nitric oxide (NO) and provides protection to immunologically active BV-2 cells with an IC50 value of 2.5 μM. Additionally, CIAC001 demonstrates anti-neuroinflammation effects in mouse models and attenuates chronic morphine-induced addiction [1].

Noxiustoxin, a toxin extracted from the venom of the Mexican scorpion Centruroides noxius, inhibits both the voltage-dependent potassium channel (Kv1.3, IC50 = 360 nM) and the calcium-activated potassium channel. It is significant in the pathophysiology of neuroinflammatory diseases [1] [2].

7-Deoxy-trans-dihydronarciclasine is an alkaloid that functions as a tobacco mosaic virus (TMV) inhibitor with an IC50 of 1.80 μM and also serves as an anti-neuroinflammatory agent. This compound reduces Aβ and APP levels in the cerebral cortex of Tg2576 mice [1] [2] [3].

NF-κB-IN-4 (compound 17) is a potent inhibitor of the NF-κB pathway that can cross the blood-brain barrier (BBB). It exhibits potential anti-neuroinflammatory activity with low toxicity, making it suitable for researching neuroinflammation-related diseases. NF-κB-IN-4 can block IκBα activation and phosphorylation, reduce NLRP3 expression, and thereby inhibit NF-κB activation [1].

Dehydromiltirone has antioxidant activity, it shows significant anti-neuroinflammatory effects through inhibiting PI3K Akt phosphorylation and then inhibiting NF-κB signaling pathway.

[12]-Dehydrogingerdione is a natural product found in ginger that has anti-neuroinflammatory activity, possibly by inhibiting the Akt IKK IκB NF-κB pathway and promoting the Nrf-2 HO-1 pathway to prevent neuroinflammation. 12-Dehydrogingerdione can inhibit the production of NO, IL-6, and PGE2 in LPS-stimulated Raw 264.7 cells.

γ-Fibrinogen377-395 is a peptide derived from fibrinogen, functioning both as an inhibitory molecule and an epitope. It inhibits microglial activation, disrupts fibrin-Mac-1 interactions in vitro, and mitigates experimental autoimmune encephalomyelitis (EAE) in murine models in vivo. This compound is relevant for research into multiple sclerosis (MS) and other neuroinflammatory disorders characterized by blood-brain barrier compromise and microglial activation [1].

Herpotrichone A exhibits strong anti-neuroinflammatory effects in BV-2 microglial cells induced by lipopolysaccharide (LPS), achieving a half maximal inhibitory concentration (IC50) of 0.41 μM.

Ferroptosis-IN-1, a diterpene derived from A. campylantha, functions as a ferroptosis inhibitor with an EC50 of 10 μM and is utilized in the study of neuroinflammatory diseases [1].

P2X7 receptor antagonist-1 is a purinergic P2X7 receptor antagonist with anti-neuroinflammatory effects.

Monoamine Oxidase B inhibitor 1 is a potent, reversible, orally active, and selective monoamine oxidase B (MAO-B) inhibitor (IC50 = 0.02 nM) capable of crossing the blood-brain barrier (BBB). It exhibits antioxidant and anti-neuroinflammatory activities and can be used in the study of Parkinson's disease[1].

20-Hydroxyganoderic acid G is a lanosterane triterpenoid obtained from the ethanolic extract of Ganoderma curtisii (Ganoderma curtisii) cotyledons. 20-Hydroxyganoderic Acid G inhibited LPS-activated BV-2 microglia, with an IC50 value of 21.33 μM. 20-Hydroxyganoderic Acid G was used to study neuroinflammatory diseases associated with LPS activation. 20-Hydroxyganoderic Acid G was used to study neuroinflammatory diseases associated with microglia activated by LPS.

CB1 antagonist 1 is a CB1 receptor antagonist, used in the research of obesity and metabolic syndrome, neuroinflammatory disorders, cognitive disorders, and gastrointestinal disorders, psychosis, and cardiovascular.

MAO-B-IN-7 is a potent and blood-brain barrier permeable MAO-B and AChE inhibitor, exhibiting IC50 values of 41 nM for human AChE, 87 nM for electric eel AChE, and 0.3 μM for MAO-B. MAO-B-IN-7 effectively alleviates oxidative stress and neuroinflammatory damage.

Shizukaol B exerts anti-inflammatory effects in LPS-activated microglia partly by modulating JNK-AP-1 signaling pathway; it also shows significant anti-neuroinflammatory effects by inhibiting nitric-oxide (NO) production in lipopolysaccharide (LPS)-stimul

MAO-B-IN-8 is a highly potent and reversible inhibitor of monoamine oxidase-B (MAO-B), also inhibiting microglial production of neuroinflammatory mediators. This compound is specifically designed for research on neurodegenerative diseases [1].